The unified social credit code/registration number of Lilly Suzhou Pharmaceutical Co., Ltd. is 9 132059460823522XC, and the corporate legal person is JULIOCESARGAYGER. At present, the enterprise is in the state of opening.
The business scope of Lilly Suzhou Pharmaceutical Co., Ltd. is: producing and processing tablets (cephalosporins), hard capsules (cephalosporins), dry suspensions (cephalosporins) and packaging imported drugs (small-volume injections, tablets and hard capsules), selling the products produced by the company and providing relevant after-sales services; Technical consultation and technical services related to new drug research and development, research and development achievements and technology transfer; Using new technologies such as slow release, controlled release, targeting and transdermal absorption, the production line of new dosage forms and new products (insulin small volume injection) was established. Economic information consulting service, enterprise management consulting and business information consulting; Engaged in the wholesale, import and export, commission agency and related supporting services of Class II medical devices, as well as the retail and related supporting services of Class II medical devices. (Projects subject to approval according to law can only be operated after approval by relevant departments). In Jiangsu Province, the total registered capital of companies with similar business scope is 879.3 million yuan, and the main capital is concentrated in enterprises with 100- 10000 and 10000-500000, * * 185. Within the scope of this province, the registered capital of mobile enterprises belongs to the general.
Lilly Suzhou Pharmaceutical Co., Ltd. invested in 0 companies and 12 branches.
See more information and materials of Lilly Suzhou Pharmaceutical Co., Ltd. through Baidu Enterprise Credit.